

Evekeo ODT™ (amphetamine sulfate) – Expanded indication, new strength

- On April 16, 2021, the FDA approved Arbor Pharmaceuticals' <u>Evekeo ODT (amphetamine sulfate)</u>, for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients 3 to 17 years of age.
 - Evekeo ODT was previously approved for this indication in patients 6 to 17 years of age.
 - Evekeo ODT is a Schedule II controlled substance.
- Evekeo ODT carries a boxed warning for abuse and dependence.
- In addition to the expanded indication, the FDA also approved a new strength (2.5 mg) of Evekeo ODT.
- The recommended starting dosage of Evekeo ODT in pediatric patients 3 to 5 years of age is 2.5 mg orally daily in the morning. If necessary, an additional dose can be administered after 4 to 6 hours. The dosage should be titrated in increments of 2.5 mg at weekly intervals depending on response and tolerability.
 - Refer to the Evekeo ODT drug label for dosing in pediatric patients 6 to 17 years of age.
 - Switching from <u>Evekeo</u> to Evekeo ODT can be done on a milligram-per-milligram basis.
 Evekeo ODT should not be substituted for other amphetamine products on a milligram-per-milligram basis because of different amphetamine salt compositions and differing pharmacokinetic profiles.
- Arbor Pharmaceuticals' launch plans for Evekeo ODT 2.5 mg are pending.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.